Document Detail


Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting.
MedLine Citation:
PMID:  22668201     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To report the functional and anatomical outcome of intravitreal bevacizumab (IVB) treatment for macular edema due to branch retinal vein occlusion (BRVO) in a clinical setting.
METHODS: The files of 45 patients treated with IVB for BRVO-induced macular edema at a tertiary medical center in 2007-2010 were reviewed. All received three loading doses (1.25 mg) and were followed every 6 weeks. Treatment was repeated for persistent or recurrent edema. If the edema did not resolve after 4-6 injections, grid laser photocoagulation was performed.
RESULTS: Mean patient age was 70.7 years (SD 8.5); mean follow-up time, 18.8 months (SD 8.3); mean number of injections, 8.8 (SD 3.8). Fourteen patients (33%) received grid laser treatment before bevacizumab and 23 (51%) after. Mean logMAR visual acuity (VA) was 0.63 (SD 0.43) before treatment (Snellen, 20/140) and 0.4 (SD 0.43) (Snellen, 20/70) after (p < 0.0005). Corresponding central macular thickness (CMT) values were 382.2 microns (SD 155.6) and 320.5 microns (SD 172.8) (p= 0.028). Positive correlations were found between initial VA and initial and final CMT (p = 0.004) and between gain in VA and reduction in CMT (p = 0.03). There was no statistically significant difference in mean initial or final VA and CMT between patients who received grid laser treatment before or during the study and those who did not.
CONCLUSIONS: IVB treatment improves visual function and reduces CMT in patients with BRVO-induced macular edema.
Authors:
Ruth Axer Siegel; Ayelet Dreznik; Karin Mimouni; Elite Bor; Dov Weinberger; Dan Haim Bourla
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2012-06-05
Journal Detail:
Title:  Current eye research     Volume:  37     ISSN:  1460-2202     ISO Abbreviation:  Curr. Eye Res.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-06     Completed Date:  2013-01-15     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8104312     Medline TA:  Curr Eye Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  823-9     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel. seegs@netvision.net.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage*
Dose-Response Relationship, Drug
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Macular Edema / diagnosis,  drug therapy*,  etiology
Male
Middle Aged
Retinal Vein Occlusion / complications*,  diagnosis
Retrospective Studies
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Primary Amine, Thiourea-Based Dual Catalysis Motif for Synthesis of Stereogenic, All-Carbon Quaterna...
Next Document:  Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and tela...